Allergy & Asthma Network Mothers of Asthmatics (AANMA) offered guidance to help patients understand recent Food and Drug Administration (FDA) warnings about Advair ® (fluticasone and salmeterol), Foradil ® (formoterol), Severent ® (salmeterol) and Symbicort ® (budesonide and formoterol), daily inhaled medications containing a long-acting beta agonist (LABA, a 12-hour bronchodilator). The FDA had two basic messages on Feb. 18: 1…

The rest is here: 
Leading Patient Education Group Provides Straight Answers To FDA’s Announcement About Asthma Medications

You may also like:

• Red Cross Blood Services Web Site Revamped; URL Changed
• Countdown To Medicare Meltdown: Day 6 - Texas Medical Association
• Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Infection
• Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review For Intravenous Acetaminophen By Three Months
• BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes
• Helix BioPharma Provides Updates On Topical Interferon Alpha-2b And L-DOS47 Following Pre-IND Meetings With The U.S. FDA
• PEGINTRON(R) Receives A Recommendation For Approval From FDA Advisory Committee For A New Application In Melanoma
• FDA Advisory Committee Recommends Gloucester Pharmaceuticals’ Romidepsin For Approval For Cutaneous T-cell Lymphoma
• APP Pharmaceuticals Receives Approval For Penicillin G Potassium For Injection, USP
• FDA Issues Complete Response Letter For Carisbamate